Cytodyn Inc (CYDY)

[jimmy667]

Good post. Yes I agree this is the most likely. It should be expected that when a treatment is so radically different in approach that it is essentially a paradigm shift that the FDA would take a close look at how to apply the new disruptive solution. The facts of these results if they bear any resemblence to the EIND patients should be undeniable and compelling. The FDA will act to make Leronlimab available for those that need it most. A primary decision initially will be to determine which patients will be given the drug due to the initial limited supply.